Recommended

AstraZeneca recruits new US biopharmaceutical executive
Lilly acquires inflammatory firm Ventyx Biosciences for $1.2bn
WEBINAR | Reflections and future opportunities in pharmaceutical microbiology
WEBINAR | Harnessing AI for more efficient clinical trials | REGISTER TODAY
Increasing the effectiveness of pharma endotoxin testing | REGISTER NOW
WEBINAR | Practical considerations for aseptic gowning in contamination control strategies
New legislation to streamline EU chemical assessment
Amgen invests $840m in Dark Blue Therapeutics
Rabbit pyrogen test removed from Eur. Ph. texts
Novo Wegovy pill first oral GLP-1RA in US for weight management
Harnessing digital PCR for rapid sterility testing | WEBINAR
Realising autonomous pharmaceutical operations | SECURE YOUR SPOT
Explore the latest issue here
Complying with USP Chapters 41 and 1251 revisions for pharma quality control | WEBINAR
news

Moderna to obtain first acquisition for $85 million

0
SHARES

Moderna has agreed on its first acquisition for $85 million, enabling it access to cell-free DNA synthesis and amplification technologies.

Moderna to obtain first acquisition for $85 million - cell-free DNA synthesis

Moderna, Inc. is set to acquire OriCiro Genomics K.K. for $85 million, who will provide expertise on cell-free DNA synthesis and amplification technologies.

 

SECURE YOUR FREE SPOT

 


This webinar to explore rapid sterility testing methods that ensure fast, reliable product release, addressing critical challenges in timely delivery and safety.

Harnessing digital PCR for rapid sterility testing | 18 March 2026 | 3PM

What you’ll discover:

  • Rapid sterility testing methods that address the challenge of lengthy testing times, improving efficiency and ensuring timely product release
  • Insights into how digital PCR technology enhances testing accuracy and sensitivity, detecting contaminants quickly and reliably
  • Real-world case studies on rapid testing implementations in the field of cell and gene therapy

A Q&A session at the end of the webinar gives the audience a chance to ask questions, such as how to implement these technologies effectively.

Register now – it’s free

“With this acquisition, we obtain best-in-class tools for cell-free DNA synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing,” commented Stéphane Bancel, Chief Executive Officer of Moderna.

Moderna’s mRNA therapeutics strategy

2022 was a pivotal year for Moderna, the company‘s CEO noted in a recent statement. Moderna’s two Omicron-targeting bivalent COVID-19 vaccines have been approved in more than 70 countries. Its platform technology also delivered the world’s first-ever mRNA cancer treatment that showed efficacy in a randomised Phase II study, demonstrating the potential of personalised medicine.

At the end 2022, Moderna, Inc. finalised a strategic partnership to create a state-of-the-art mRNA vaccine research, development, and manufacturing facility in the UK. The site, called the Moderna Innovation and Technology Centre (MITC) is designed to provide access to a UK-made supply of COVID-19 vaccines. The facility also offers potential for the development of vaccines for other respiratory illnesses, such as flu and respiratory syncytial virus (RSV).

The future mRNA therapeutic market

A 2022 market report forecasted that mRNA non-vaccine therapeutics are set to generate $2 billion in sales by 2028. The research found that since the COVID-19 pandemic, there has been a spike in interest in mRNA therapeutics, due to the success of mRNA vaccines treating the virus.

mRNA therapeutics: a limitless revolution in medicine

 
Share via
Share via